GlassScriptPhysician profile
Fatema Omran
NPI 1205865862
$610.35
in general payments reported to CMS, 2019-2025
15 companies · $452 in 2025
The $452 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2023: $13.39 · 2024: $25.35 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $490.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $120.14 | 2025 | Korlym |
| Galderma Laboratories, L.P. | $119.93 | 2021 | |
| Xeris Pharmaceuticals, INC. | $52.58 | 2025 | Gvoke Hypopen |
| Radius Health, INC. | $50.56 | 2025 | Tymlos |
| Tandem Diabetes Care, INC. | $33.51 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Neurocrine Biosciences, INC. | $32.20 | 2025 | |
| Dexcom, INC. | $30.45 | 2025 | Dexcom G6 Transmitter |
| Madrigal Pharmaceuticals | $26.50 | 2025 | Rezdiffra |
| Chiesi USA, INC. | $25.35 | 2024 | Mycapssa |
| Ascendis Pharma Endocrinology INC | $23.40 | 2025 | Yorvipath |
| Sanofi-Aventis U.S. LLC | $23.20 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.80 | 2025 | |
| Recordati_rare_diseases_inc. | $20.08 | 2025 | Isturisa |
| Novo Nordisk INC | $17.26 | 2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $13.39 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatema Omran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.